SPNT Stock Analysis: Siriuspoint | NYSE
Insurance - Reinsurance | NYSE, USA | Market Cap: 2.945m USD | 12M Return: 36.7% | BMG8192H1060 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 18.0M
EPS Trend: 42.1%
Qual. Beats: 0
Rev. Trend: 74.6%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
SiriusPoint Ltd. (SPNT) is a Bermuda-domiciled provider of multi-line reinsurance and insurance products, operating through four segments: Global P&C Programs, Global Reinsurance, Global Accident & Health, and London Market Specialty.
The company underwrites casualty, property, aviation and space, marine and energy, and credit risks, serving insurance companies, government entities, and other risk-bearing vehicles. Its Accident & Health segment includes medical insurance, trip cancellation programs, medical management, and 24/7 emergency medical and travel assistance services.
Bermuda is a major global hub for reinsurance, attracting carriers through its specialized regulatory and tax framework. SiriusPoint was incorporated in 2011, is headquartered in Pembroke, and rebranded from Third Point Reinsurance Ltd. in February 2021.
- Catastrophe losses pressure underwriting margins
- Reinsurance pricing hardens boosting premium rates
- Investment income expands on higher yields
| Net Income: 505.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA 0.80 > 1.0 |
| NWC/Revenue: -26.93% < 20% (prev -49.82%; Δ 22.90% < -1%) |
| CFO/TA 0.02 > 3% & CFO 243.2m > Net Income 505.6m |
| Net Debt (-5.20b) to EBITDA (683.1m): -7.62 < 3 |
| Current Ratio: 0.91 > 1.5 & < 3 |
| Outstanding Shares: last quarter (119.0m) vs 12m ago -26.25% < -2% |
| Gross Margin: 50.52% > 18% (prev 25.02%; Δ 25.50% > 0.5%) |
| Asset Turnover: 25.96% > 50% (prev 21.41%; Δ 4.55% > 0%) |
| Interest Coverage Ratio: 8.85 > 6 (EBIT TTM 672.9m / Interest Expense TTM 76.0m) |
| A: -0.07 (Total Current Assets 8.55b - Total Current Liabilities 9.43b) / Total Assets 12.7b |
| B: 0.11 (Retained Earnings 1.40b / Total Assets 12.7b) |
| C: 0.05 (EBIT TTM 672.9m / Avg Total Assets 12.5b) |
| D: 0.22 (Book Value of Equity 2.28b / Total Liabilities 10.4b) |
| Altman-Z'' = 0.50 = B |
As of November 04, 2026, the stock is trading at USD 25.80 with a total of 803,466 shares traded. Over the past week, the price has changed by +1.78%, over one month by +5.31%, over three months by +9.14% and over the past year by +36.65%.
Current recommended Stop Loss: 24.60 (which is 4.7% or 2.1 ATR below the current price).
Siriuspoint has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy SPNT.
- StrongBuy: 2
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 28.8 | 11.4% |
P/E Trailing = 6.2438
P/E Forward = 9.3023
P/S = 0.9814
P/B = 1.3153
Revenue TTM = 3.25b USD
EBIT TTM = 672.9m USD
EBITDA TTM = 683.1m USD
Long Term Debt = 675.5m USD (from longTermDebt, last quarter)
Short Term Debt = 3.50m USD (from shortTermDebt, last quarter)
Debt = 700.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -5.20b USD (calculated: Debt 700.9m - CCE 5.90b)
Enterprise Value = 2.94b USD (floored to Market Cap, CCE > MCap+Debt)
Interest Coverage Ratio = 8.85 (Ebit TTM 672.9m / Interest Expense TTM 76.0m)
EV/FCF = 12.11x (Enterprise Value 2.94b / FCF TTM 243.2m)
FCF Yield = 8.26% (FCF TTM 243.2m / Enterprise Value 2.94b)
FCF Margin = 7.49% (FCF TTM 243.2m / Revenue TTM 3.25b)
Net Margin = 15.58% (Net Income TTM 505.6m / Revenue TTM 3.25b)
Gross Margin = 50.52% ((Revenue TTM 3.25b - Cost of Revenue TTM 1.61b) / Revenue TTM)
Gross Margin QoQ = 51.86% (prev 53.15%)
Tobins Q-Ratio = 0.23 (Enterprise Value 2.94b / Total Assets 12.7b)
Interest Expense / Debt = 10.84% (Interest Expense 76.0m / Debt 700.9m)
Taxrate = 15.30% (91.3m / 596.9m)
NOPAT = 570.0m (EBIT 672.9m * (1 - 15.30%))
Current Ratio = 0.91 (Total Current Assets 8.55b / Total Current Liabilities 9.43b)
Debt / Equity = 0.31 (Debt 700.9m / totalStockholderEquity, last quarter 2.28b)
Debt / EBITDA = -7.62 (Net Debt -5.20b / EBITDA 683.1m)
Debt / FCF = -21.39 (Net Debt -5.20b / FCF TTM 243.2m)
Total Stockholder Equity = 2.31b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.04% (Net Income 505.6m / Total Assets 12.7b)
RoE = 21.84% (Net Income TTM 505.6m / Total Stockholder Equity 2.31b)
RoCE = 22.51% (EBIT 672.9m / Capital Employed (Equity 2.31b + L.T.Debt 675.5m))
RoIC = 18.60% (NOPAT 570.0m / Invested Capital 3.07b)
WACC = 5.70% (E(2.94b)/V(3.65b) * Re(4.87%) + D(700.9m)/V(3.65b) * Rd(10.84%) * (1-Tc(0.15)))
Discount Rate = 4.87% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -92.14 | Cagr: -15.62%
[DCF] Terminal Value 77.97% ; FCFF base≈201.5m ; Y1≈231.0m ; Y5≈340.0m
[DCF] Fair Price = 88.82 (EV 5.12b - Net Debt -5.20b = Equity 10.3b / Shares 116.2m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 42.14 | EPS CAGR: 19.89% | SUE: 0.08 | # QB: 0
Revenue Correlation: 74.62 | Revenue CAGR: 7.26% | SUE: -0.04 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.64 | Chg30d=+11.17% | Revisions=+25% | Analysts=5
EPS current Year (2026-12-31): EPS=2.66 | Chg30d=+2.11% | Revisions=+25% | GrowthEPS=+4.3% | GrowthRev=-3.6%
EPS next Year (2027-12-31): EPS=2.76 | Chg30d=+0.00% | Revisions=+25% | GrowthEPS=+3.8% | GrowthRev=+5.6%
[Analyst] Revisions Ratio: +50% (up=3, down=0)